ZD 1839 "Iressa";Le ZD 1839: « Iressa »

Bulletin du Cancer

Volumn 87, Issue 12, 2000, Pages 873-876

  Meric, J B ^a   Faivre, S ^a   Monnerat, C ^a   Adi Vago, N ^a   Le Chevalier, T ^a   Armand, J P ^a   Raymond, E ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

EGF; Phase I; Tyrosine kinase; ZD 1839

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; RASH; REVIEW; SIGNAL TRANSDUCTION; VOMITING; ANIMAL; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; HALF LIFE TIME; MOUSE; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CLINICAL TRIALS, PHASE I; ENZYME INHIBITORS; HALF-LIFE; HUMANS; MICE; NEOPLASMS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0034500428     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Tyrosine kinases in disease : Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
2. Relationship between EGF-R c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormonal sensitivity
3. Epidermal growth factor-related peptides and their receptors in human malignancies
4. Cetuximab
5. ZD 1839 (« Iressa »), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGRF-TKI): Correlation of c-fos expression and tumour growth inhibition
6. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
7. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD 1839
8. ZD 1839 « Iressa », an epidermal growth factor receptor tyrosine kinase inhibitor, decreases epithelial proliferation in DCIS of the breast, whereas c-erbB2 monoclonal antibody (trastuzumab) blokade does not
9. Potentiation of cytotoxic agents against human tumors in mice by ZD 1839 (« Iressa »), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
10. Low dose cisplatin can modulate the sensitivity of human non small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD 1839, « Iressa ») in vivo
11. Phase I data of ZD 1839 - An oral epidermal growth factor receptor tyrosine kinase inhibitor
12. Intermittent oral ZD 1839 (« Iressa »), a novel epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results of a phase I study
13. ZD 1839 (« Iressa »), an oral EGFR-TKI (epidermal growth factor tyrosine kinase inhibitor): Pharmacokinetic results of a phase I study in patients with advanced cancer
14. A phase I intermittent dose-escalation trial of ZD 1839 (« Iressa ») in Japanese patients with solid malignant tumors
15. A phase I intermittent dose-escalation trial of ZD 1839 (« Iressa ») in Japanese patients with solid tumors
16. NCIC CTG IND. 122: A multicenter phase I dose-escalation study of ZD 1839 with pharmacodynamic (PD) end points: Feasibility of serial tumor sampling